Prasinezumab Fails to Slow Symptom Worsening in Parkinson’s, But Shows Other Signs of Effectiveness, Trial Finds

Prasinezumab Fails to Slow Symptom Worsening in Parkinson’s, But Shows Other Signs of Effectiveness, Trial Finds
Prasinezumab (PRX002/RG7935), an antibody designed to eliminate the toxic clumps of alpha-synuclein in Parkinson’s disease patients, did not lessen the progression of motor and non-motor symptoms over one year, compared with a placebo, findings from a Phase 2 clinical trial show. While the results mean that the PASADENA study (NCT03100149) did not achieve its primary goal, Roche — which is developing ... read more
Source: Parkinson’s News TodayPublished on 2020-04-24By Ines Martins, PhD